Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.
In one study, 732 patients with primary progressive MS were randomized on a 2:1 ratio to receive either ocrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, or a placebo.
The proportion of patients with 12-week confirmed disability progression was 39.3 per cent with the placebo versus 32.9 per cent with ocrelizumab. After 24 weeks, the proportion with confirmed disability progression was 35.7 per cent with placebo versus 29.6 per cent with ocrelizumab. By week 120, timed 25-foot walk worsened by 55.1 per cent for placebo versus 38.9 per cent for ocrelizumab. Patients given ocrelizumab were also found to have fewer new brain lesions and less brain volume loss than those given the placebo.
Researchers also tested ocrelizumab in two separate studies of patients with relapsing remitting MS, one a group of 821 and the other 835. In both studies, patients were randomized on a 1:1 ratio to receive either ocrelizumab or an already established treatment for relapsing MS: subcutaneous interferon-beta, injected three times weekly. Compared to the placebo, relapse rates in patients given ocrelizumab were 46-per-cent lower in one study and 47-per-cent lower in the other. Ocrelizumab was found to reduce the risk of disability progression after 12 weeks and 24 weeks, and reduced the number of new brain lesions.
The study noted that infusion-related reactions occurred in 34.3 per cent of ocrelizumab-treated patients. Serious infections were not more frequent with ocrelizumab compared to the interferon (1.3 versus 2.9 per cent respectively). Malignancies occurred in four ocrelizumab-treated patients and in two interferon-treated patients. Further observation is required to determine the long-term safety of ocrelizumab.
“The results in patients with relapsing remitting MS not only demonstrate very high efficacy against relapses, but also underscore the important emerging role of B cells of the immune system in the development of relapses,” says Bar-Or. “While the results in patients with primary progressive MS are more modest, they nonetheless represent the very first successful trial in such patients, a breakthrough as primary progressive MS now transitions from a previously untreatable condition to one that can be impacted by therapy. It is an important step forward in the field.”
These studies, funded by Roche, were published in the New England Journal of Medicine on Dec. 21, 2016.
MS in Canada
Canada has one of the world’s highest rates of MS – about 1,100 new cases each year. Some 50,000 Canadians have MS, and more than one-in-five patients are in Quebec. MS is one of the most common neurological diseases among young Canadians. Children as young as two can develop the disease. It typically strikes people in their prime years, between 15 and 40. Women are twice as likely as men to contract MS.
Learn more: Breakthrough in MS treatment
Receive an email update when we add a new MULTIPLE SCLEROSIS article.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Managing Multiple Sclerosis Relapseson June 26, 2020 at 12:12 pm
Recently, ZEPOSIA® (ozanimod), a new oral therapy, was approved by the U.S. Food and Drug Administration to treat adult patients with relapsing forms of multiple sclerosis, including clinically ...
- Clinical characteristics, outcomes in patients with COVID-19, multiple sclerosison June 26, 2020 at 8:21 am
What The Study Did: The clinical characteristics and outcomes in patients with multiple sclerosis who contract COVID-19 are described in this observational study, which identifies factors associated ...
- Multiple Sclerosis Drugs Market 2020 Top Manufacturers, Industry Share, Size, Regional Analysis, Types and Applications and Forecasts to 2025on June 26, 2020 at 4:54 am
Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Multiple Sclerosis Drugs ...
- BRIEF-Geneuro Enrolls First Patient In Temelimab Phase 2 Multiple Sclerosis Trialon June 24, 2020 at 10:45 pm
GENEURO ENROLLS FIRST PATIENT IN TEMELIMAB PHASE 2 MULTIPLE SCLEROSIS TRIAL IN COLLABORATION WITH THE KAROLINSKA INSTITUTET’S ACADEMIC SPECIALIST CENTER (ASC) * GENEURO SA - ONE-YEAR SINGLE CENTER ...
- GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC)on June 24, 2020 at 10:30 pm
Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving th ...
- New MyMSTeam Resource Center Educates People Living With Multiple Sclerosis On The Importance of Treatment and Adherenceon June 24, 2020 at 9:30 am
Today, MyHealthTeams and EMD Serono, through their MS-LINK initiative, announced the launch of the Treatment and Adherence Resource Center within MyMSTeam, the social network for (MS). The ...
- Disease-modifying therapy aids cognition in multiple sclerosison June 24, 2020 at 2:19 am
A new meta-analysis indicates that multiple sclerosis disease-modifying therapies (DMTs) have positive effects on cognition. High-efficacy and medium-efficacy DMTs apparently had comparable cognitive ...
- Biogen Can Bounce Back from Multiple-Sclerosis Blowon June 18, 2020 at 9:31 am
The biotech company has suffered a surprise blow to its blockbuster multiple sclerosis franchise. It has a chance to recover, but investors should expect a bumpy ride.
- Multiple Sclerosis Drugs Market: New Multiple Sclerosis Medication in Research Pipeline Promises Better Resultson June 18, 2020 at 8:46 am
Introduction In terms of revenue, the multiple sclerosis drugs market is projected to expand at a CAGR of ~6% during the ...
via Bing News